Shares

6 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2022

May 20, 2022

SELL
$69.73 - $142.9 $207,655 - $425,556
-2,978 Closed
0 $0
Q4 2021

Feb 15, 2022

SELL
$134.56 - $217.97 $29,872 - $48,389
-222 Reduced 6.94%
2,978 $239,000
Q3 2021

Nov 12, 2021

SELL
$177.8 - $270.58 $369,112 - $561,724
-2,076 Reduced 39.35%
3,200 $663,000
Q2 2021

Aug 02, 2021

BUY
$121.0 - $257.67 $261,723 - $557,340
2,163 Added 69.48%
5,276 $1.02 Million
Q1 2021

Apr 28, 2021

BUY
$112.98 - $319.93 $147,551 - $417,828
1,306 Added 72.27%
3,113 $690,000
Q4 2020

Jan 27, 2021

BUY
$78.74 - $139.5 $142,283 - $252,076
1,807 New
1,807 $229,000

Others Institutions Holding NVAX

About NOVAVAX INC


  • Ticker NVAX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 78,215,104
  • Market Cap $731M
  • Description
  • Novavax, Inc., a biotechnology company, focuses on the discovery, development, and commercialization of vaccines to prevent serious infectious diseases and address health needs. The company's vaccine candidates include NVX-CoV2373, a coronavirus vaccine candidate that is in two Phase III trials, one Phase IIb trial, and one Phase I/II trial; Nan...
More about NVAX
Track This Portfolio

Track Chicago Partners Investment Group LLC Portfolio

Follow Chicago Partners Investment Group LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Chicago Partners Investment Group LLC, based on Form 13F filings with the SEC.

News

Stay updated on Chicago Partners Investment Group LLC with notifications on news.